PPIs linked to risk of acute kidney injury in elderly
Older adults taking proton pump inhibitors (PPIs) were more likely to have an increased risk of acute kidney injury and acute interstitial nephritis, according to a study published in CMAJ Open.
Older adults taking proton pump inhibitors (PPIs) were more likely to have an increased risk of acute kidney injury and acute interstitial nephritis, according to a study published in CMAJ Open.
PPIs are used to treat heartburn, gastroesophageal reflux disease (GERD), and gastric ulcers. Common PPIs include esomeprazole (Nexium), lansoprazole (Prevacid), and omeprazole (Prilosec).
Related:FDA approves first generic version of Nexium
Lead study author Tony Antoniou, PhD, a researcher at the Institute for Clinical Evaluative Sciences and St. Michael's Hospital in Toronto, and colleagues conducted a population-based study involving 290,592 Ontario residents aged 66 years and older who initiated PPI therapy between April 1, 2002, and November 30, 2011. They used propensity score matching to establish a highly comparable reference group of control patients. The primary outcome was hospital admission with acute kidney injury within 120 days, and a secondary analysis examined acute interstitial nephritis. They used Cox proportional hazards regression to adjust for differences between groups.
The rates of acute kidney injury (13.49 v. 5.46 per 1,000 person-years, respectively; hazard ratio [HR] 2.52, 95% CI 2.27 to 2.79) and acute interstitial nephritis (0.32 vs. 0.11 per 1,000 person-years; HR 3.00, 95% CI 1.47 to 6.14) were higher among patients given PPIs than among controls.
Related:Ranbaxy blocked from launching generic Nexium, Valcyte
“These are potentially reversible conditions that may not be readily attributed to drug treatment. Clinicians should maintain a high index of suspicion for these adverse effects among patients who are prescribed proton pump inhibitors,” Antoniou said.
“Although the absolute risk of acute kidney injury with proton pump inhibitors is low, these drugs are used by millions of people each year,” he said. “Our results underscore the importance of ongoing efforts to curtail the indiscriminate use of these drugs. When these drugs are indicated, the need for their ongoing use should be periodically reappraised.”
Read next:[BLOG] Pipeline advancement responsible for upturn in global pharma R&D
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
